Flow cytometric analysis of Human PBMCs (human peripheral blood mononuclear cells) labeled with anti – Human CD19 antibody at 1/1000 dilution (0.5 μg) / (right panel) compared with a Mouse IgG1 Isotype Control / (left panel). Goat Anti- Mouse IgG Alexa Fluor® 488 was used as the secondary antibody. Then cells were stained with CD3 - Brilliant Violet 421™ antibody separately. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Invivo anti-Human CD19 Recombinant mAb
Invivo anti-Human CD19 Recombinant mAb
Price:
Regular price
$175 USD
Regular price
Sale price
$175 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD19 |
| Synonyms | B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12 |
| Location | Cell membrane |
| Accession | P15391 |
| Clone Number | 4G7 |
| Antibody Type | Mouse mAb |
| Isotype Control | S0B0760 |
| Application | FCM, Functional assays |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein G |
| Concentration | 5 mg/ml |
| Purity | >95% (Determined by SDS-PAGE) |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Dilution
| application | dilution | species |
| FCM | 1:1000 | Hu |
Background
CD19, also known as B-lymphocyte antigen CD19 or B-Lymphocyte Surface Antigen B4, is a 95 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily and is encoded by the CD19 gene. It is primarily expressed on all B lineage cells, from early pro-B cells to plasma cells, and plays a crucial role in B cell development, activation, and signaling. As a co-receptor, CD19 enhances signaling through the B cell receptor (BCR) complex, lowering the threshold for B cell activation and promoting B cell proliferation and differentiation. It forms a complex with CD21, CD81, and other proteins, which helps in the recognition of antigens tagged with complement and amplifies BCR signaling. CD19 is also a biomarker for B cell-related diseases and a target for immunotherapies, including monoclonal antibodies and CAR-T cell therapies, due to its consistent expression on B cells and B cell malignancies.
Picture
Picture
FC
